Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

Abstract: A surgical robotic system and a method of controlling a location of one or more robotic arms in a constrained space are disclosed herein. In some embodiments, the robotic system includes a robotic unit having robotic arms. The system further includes a camera assembly to generate a view an anatomical structure of a patient. The system further includes a controller configured to or programmed to define a constriction area defining safe movement of the robotic arms. The method includes defining safe movement of the robotic arms with respect to the constriction area.

Abstract: The present invention relates to the use of a plasmid encoding Staphylococcus aureus polypeptides and its use in the preparation of compositions and vaccines. More specifically, the present invention is concerned with compositions, DNA vaccines and methods for providing an immune response and/or a protective immunity into mammals against a Staphylococcus aureus associated disease, such as mastitis. The plasmid used in the composition or DNA vaccine comprises at least one nucleotide coding sequence of a Staphylococcus aureus polypeptide, such as the Clumping factor A (ClfA), the fibronectin-binding protein A, the sortase-A or the pre-pheromone (ArgD).

Abstract: The present invention relates to a DNA plasmid vaccine for immunization of animals against BVDV which comprises at least a mammalian expression vector having a DNA sequence encoding at least one BVDV immunogenic protein or fragment thereof which is selected from the group consisting of BVDV major glycoprotein gp53/E2, p20 (Npro), p14/C, gp48/E0, gp25/E1 and p80/NS3 proteins, the immunogenic protein is operably linked downstream from a suitable promoter for its expression, whereby inducing a BVDV-specific antibody responses.